Background--Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that predominantly affects women and is associated with prevalent hypertension, renal injury, and cardiovascular disease. Immune system dysfunction is recognized as an important factor in the pathogenesis of hypertension. We recently showed that preventing autoimmunity prevents the development of hypertension in an experimental model of SLE (female NZBWF1 mice). The present study tests the hypothesis that mycophenolate mofetil (MMF), an immunosuppressive therapy used clinically to treat SLE by depleting proliferating B and T lymphocytes, can improve blood pressure control.
A daptive immune system dysfunction has been implicated in the pathogenesis of hypertension for several decades. Patients with, for example, essential hypertension or pregnancy-associated hypertension have been shown to have elevated circulating levels of IgG and IgM, [1] [2] [3] [4] and additional studies have shown the presence of autoantibodies specific for host proteins such as the angiotensin II type 1 receptor 5 and the a1-adrenergic receptor, 6 among others, in hypertensive patients. These studies suggest a role for abnormal B-cell activity in the pathogenesis of hypertension in certain patient populations and highlight the potential link between autoimmunity and hypertension.
Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune inflammatory disorder that predominantly affects women of childbearing age and is characterized by B and T lymphocyte hyperreactivity and the production of pathogenic autoantibodies, often to nuclear components. These autoantibodies form abnormal immune complexes that deposit in various tissues, including the kidneys, skin, joints, and central nervous system. SLE is associated with prevalent hypertension, [7] [8] [9] [10] [11] [12] which contributes to the high risk of cardiovascular disease, which is the major cause of mortality in these patients. [13] [14] [15] [16] We recently demonstrated that systemic autoimmunity is a key factor in the development of hypertension in an experimental mouse model of SLE with hypertension (female NZBWF1). 17 Nevertheless, the effect of immunosuppression on hypertension in SLE patients remains poorly understood. Mycophenolate mofetil (MMF) is an immunosuppressant that was initially used to prevent organ transplant rejection and has emerged as a frontline agent for both induction 18 and maintenance therapy 19 in patients with lupus nephritis. MMF inhibits the inducible type II isoform of inosine monophosphate dehydrogenase, which is specifically expressed by activated T and B lymphocytes. 20 It effectively lowers blood pressure in some hypertensive animal models, including spontaneously hypertensive rats 21 and Dahl SS rats, 22, 23 but not others (ie, angiotensin II hypertension 24 ). In human hypertension, a small clinical study of patients with the autoimmune diseases psoriasis and rheumatoid arthritis revealed that MMF treatment effectively lowered arterial blood pressure. 25 It is not clear, however, if MMF has similarly beneficial blood pressure effects during SLE. Because of the prevalent hypertension associated with SLE and the widespread use of MMF in this patient population, understanding the impact of MMF on blood pressure is likely to have direct clinical relevance for SLE patients. Harbor, ME) were used in this study. Mice were maintained on a 12-hour light/dark cycle in temperature-controlled rooms with access to chow and water ad libitum. All studies were performed with the approval of the University of Mississippi Medical Center (UMMC) institutional animal care and use committee and in accordance with National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Materials and Methods

MMF Administration
MMF (CellCept Intravenous; Genentech) was dissolved in sterile 5% dextrose. Mice were administered 60 mg/kg per day IP for 8 weeks in a volume of 0.1 mL. Mice not receiving MMF were injected with 0.1 mL 5% dextrose (vehicle).
Blood Pressure
Mean arterial pressure (in mm Hg) was recorded via indwelling carotid artery catheters in freely moving conscious mice, as described previously by our laboratory.
17,26-29
Preparation of Cells for Flow Cytometry
Blood was collected from the retro-orbital plexus from MMF-or vehicle-treated animals at 27 week (0 weeks MMF), 31 weeks (4 weeks MMF), and 35 weeks (8 weeks MMF). The blood was centrifuged at 350g to isolate plasma. Erythrocytes were lysed by adding 109 volume of 1X PharmLyse (BD Biosciences). After incubation for 5 minutes at room temperature, blood was centrifuged at 200g for 5 minutes. The pelleted cells were washed in 1X PBS and 2% FCS and centrifuged at 350g for 5 minutes. The purified peripheral blood leukocytes were suspended in 90% FCS and 10% dimethyl sulfoxide and stored at À80°C until use. For isolation of renal immune cells, 1 kidney was homogenized in 5 mL RPMI media containing 200 U/mL DNase and 10 mg/mL collagenase IV using the GentleMACS Octo Dissociator (Miltenyi Biotec) using a user-defined protocol for mouse kidney. The resulting homogenate was filtered through a 70-lmol/L cell strainer and washed with 1X PBS containing 2% FCS and 2 mmol/L EDTA. The single-cell suspension was centrifuged at 300g for 10 minutes. The resulting cell pellet was then resuspended in 1X PBS and 2% FCS. Peripheral blood leukocytes were isolated from the kidney cell suspension using Lymphoprep (Accurate Chemical), according to the manufacturer's instructions.
Flow Cytometric Analyses
Cells were resuspended in 1X PBS, 2% FCS, and 0.9% sodium azide at a concentration of 2910 7 cells/mL. Next, 1910 6 cells (50 lL) were aliquoted into a flow cytometry tube and incubated with 0.5 lg of anti-mouse CD32/CD16 (FcR block; BD Biosciences) for 5 minutes on ice. Cells were then stained with isotype control antibodies; a T-cell subset antibody cocktail (BD Biosciences) that contains anti-mouse CD3e-PECy7 (clone 145-2C11), CD4-PE (clone RM4-5), and CD8-APC (clone 53-6.7); or anti-CD45R-PE-Cy7 (clone RA3-6B2). Cells were incubated on ice for 30 minutes protected from light. Samples were analyzed on a Gallios (Becton Dickinson) flow cytometer at the UMMC flow cytometry core facility. A total of 25 000 events were acquired for each sample. Data were analyzed using Kaluza software (Beckman Coulter).
Autoantibodies
Anti-double-stranded DNA (anti-dsDNA) IgG was detected in plasma at 27 and 35 weeks of age (SLE mice) or 36 weeks of age (control mice) using the anti-dsDNA IgG ELISA (Alpha Diagnostic International) per the manufacturer's instructions and as previously described by our laboratory. 17, 26, 28, 29 Isotype-specific ELISAs were prepared according to the method of Mihara et al. 30 Briefly, plates were coated with salmon sperm DNA, incubated with diluted plasma from vehicle-and MMF-treated SLE mice, and probed with horseradish peroxidase-conjugated antibodies specific for each mouse antibody isotype.
Renal Injury
Urinary albumin was monitored weekly by dipstick analysis (Albustix; Siemens). Animals were considered positive for albuminuria at ≥100 mg/dL. 17, 26, 27, 29 Urinary albumin excretion rate (in mg/day) was assessed by ELISA (Alpha Diagnostic International) using overnight urine samples collected at the conclusion of the study, as described previously. 17, 26, 27, 29 Glomerulosclerosis was assessed using Masson's trichrome, as described previously by our laboratory. 17 
Statistical Analysis
Data are presented as meanAESEM. Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software 
Results
Because MMF depletes activated B and T lymphocytes, we analyzed circulating B and T cells at the onset of the treatment (aged 27 weeks) and after 4 weeks (aged 31 weeks) and 8 weeks (aged 35 weeks) of MMF, at the end of the study, using flow cytometry. Figure 1A shows representative histograms from SLE mice treated with vehicle or MMF at the indicated time points, and Figure 1B (Figure 2A ). In addition, no differences in the percentage of CD3 + CD8 + T cells were detected between the 2 treatment groups (Figure 2B) . No changes were detected in B or T cells in control mice treated with vehicle or MMF ( Figure 3 ). Total plasma anti-dsDNA IgG autoantibody production was increased in SLE mice compared with control (107.7AE23.2 versus 769.6AE114.9 U/mL, P<0.01) (Figure 4A ), in agreement with previous reports by our laboratory. 17 Figure 5 ). To analyze the effect of MMF on hypertension in SLE, mean arterial pressure was measured in conscious, freely moving mice at the conclusion of the study. Vehicle-treated SLE mice had elevated mean arterial pressure compared with vehicletreated control mice, consistent with our previous studies (141AE3 versus 120AE3 mm Hg, P<0.01) (Figure 6 ). Blood pressure was significantly lower in SLE mice treated with MMF compared with SLE mice treated with vehicle (120AE4 versus 141AE3 mm Hg, P<0.01), whereas MMF treatment did not affect blood pressure in control mice (120AE3 versus 117AE4 mm Hg).
Mice with SLE develop renal injury and excrete large amounts of albumin in their urine. Consistent with previous studies in our laboratory, 17, 26, 32, 33 40% of the vehicle-treated treated with MMF developed albuminuria ( Figure 7A ). Urinary albumin excretion measured at the conclusion of the study was greater in vehicle-treated SLE mice compared with control mice (3.95AE2 versus 0.043AE0.02 mg/day). SLE mice treated with MMF had a lower albumin excretion rate (0.27AE0.007 mg/ day) compared with vehicle-treated SLE mice ( Figure 7B ). MMF treatment had no effect on albumin excretion in control mice treated with vehicle (0.043AE0.02 mg/day) versus MMF (0.052AE0.03 mg/day). In addition to attenuating the development of albuminuria, MMF treatment prevented the development of glomerulosclerosis ( Figure 7C ). Vehicle-treated SLE mice had a significantly higher glomerulosclerosis index compared with vehicle-treated control mice (2.8AE0.35 versus 0.14AE0.05, P<0.01) ( Figure 7D ). Glomerular injury was significantly lower in MMF-treated SLE mice (0.63AE0.27, P<0.01 compared with vehicle-treated SLE mice).
The accumulation of leukocytes in the kidneys mechanistically contributes to the pathogenesis of hypertension. [34] [35] [36] [37] Isolated kidney leukocytes were stained with antibodies specific to B cells (CD45R) and T cells (CD3/CD4/CD8) and 
Discussion
Patients with SLE have a high incidence of hypertension, renal injury, and cardiovascular disease. Our laboratory previously showed that impaired renal hemodynamic function, 28 peripheral vascular function, 31 increased oxidative stress, 26 and altered inflammatory cytokine production 32, 38 contribute to hypertension in an established female mouse model of SLE. We hypothesize that these reported changes result from the loss of immune tolerance and lead to the production of autoreactive B and T lymphocytes. The present study directly tested whether immunosuppression with the drug MMF, used clinically for the treatment of SLE, would attenuate hypertension in an experimental model of SLE. The major new findings of this study are that MMF treatment (1) depleted circulating B lymphocytes and lowered anti-dsDNA autoantibody production in SLE mice, independent of any effects on circulating T cells; (2) successfully attenuated the development of SLEassociated hypertension and renal injury; and (3) reduced lymphocyte infiltration into the kidneys as a likely mechanism contributing to antihypertensive effects. MMF was initially shown to attenuate lupus nephritis and to prolong life in both MRL/lpr and NZBWF1 mice when administered chronically starting at 8 to 12 weeks of age. [39] [40] [41] Dosages of 30 to 200 mg/kg per day were used in these studies, although data conflict concerning the efficacy of MMF for depleting T and B lymphocytes. Two studies reported no change in the relative percentages of T and B lymphocytes in either the peripheral blood or spleen. 40, 41 Conversely, another study found that a 7-week treatment of MRL/lpr mice with MMF (100 mg/kg per day) resulted in a significant decrease in the percentage of circulating CD3 + CD4 À CD8 À T cells, 42 which are known to accumulate in the MRL/lpr model. 43 Although there were no differences in T cells between vehicle-and MMFtreated mice, there was a decrease in circulating CD3 + CD4 + T cells over the course of the study in both groups. This decrease in T cells could be the result of lymphopenia due to SLE disease progression. 44, 45 Specifically, CD4 + T cell levels have been shown to be depressed in some patients with SLE. 46 In the present study, we demonstrated that after 4 weeks of MMF treatment, SLE mice had almost no circulating CD45R + B cells, but by 8 weeks of treatment, the efficacy of MMF for depleting B cells was reduced. Despite the reduced ability of MMF to deplete B cells, it is important to note that the production of autoantibodies remained markedly attenuated. This contrasts with the vehicle-treated mice that displayed a progressive and significant increase in the percentage of both CD45R + B cells and autoantibodies over the course of the study. The reason for the loss of MMF efficacy in depleting B cells is unclear, although it is possible that the mice became desensitized and that antibody production would have risen if the study had been carried out longer. It is also possible that using higher dosesreportedly well tolerated by SLE mice 40, 47 -would have resulted in sustained depletion of B cells and could have altered T-cell percentages. Nevertheless, our results using the selected dose serendipitously depleted circulating B cells and lowered anti-dsDNA IgG production, independent of changes in T cells. This suggests that autoreactive B cells have an important mechanistic role in the pathogenesis of SLE-associated hypertension. It may be that the depletion of B cells by MMF early in the study resulted in decreased differentiation into long-lived plasma cells, which are known to be important producers of autoantibodies in SLE that are not depleted by MMF. 48 Fewer autoreactive plasma cells would likely result in sustained decreases in autoantibody production. It should be noted that in patients with SLE, treatment with MMF reduces surrogate markers of B-cell activation, including circulating plasmablasts and plasma cells during induction therapy. 49, 50 The impact of MMF 60 mg/kg per day, used in the present study, on autoantibody production in mice with SLE is consistent with the work of others. 39 Ramos et al showed that a lower dose of MMF (30 mg/kg per day) in NZBWF1 mice selectively reduced anti-dsDNA IgG2a autoantibodies and that a higher dose (100 mg/kg per day) inhibited the production of all anti-dsDNA autoantibodies, regardless of isotype. 47 The findings of the current study showing that 8- Figure 6 . Effect of mycophenolate mofetil (MMF) treatment on mean arterial pressure (MAP) in control and systemic lupus erythematosus (SLE) mice treated with MMF. MAP was significantly higher in SLE compared with control mice. MMF significantly lowered blood pressure in SLE mice but had no effect in control mice. *P<0.01 vs all other groups.
week treatment with MMF significantly lowered anti-dsDNA IgG1 autoantibody production and qualitatively lowered IgG2a and IgG2b production in SLE mice without affecting IgG3 and IgM anti-dsDNA autoantibody production further advances the understanding of how MMF affects autoantibody production. The IgG2a and IgG2b isotypes are generally considered the most pathogenic in mice because they can efficiently bind to FccRIII and FccRIV, leading to complement activation, whereas IgG1 can bind FccRIII but cannot fix complement via the classical pathway. 51 In general, the role of autoantibodies in the pathogenesis of hypertension is poorly understood in both animal models and humans, although mounting evidence suggests their importance in patients with essential hypertension and pregnancy-associated hypertension. For example, antibodies specific for the angiotensin type I receptor, a1-adrenergic receptor, and L-type voltage gated calcium channels have been identified in patients with essential hypertension, 5, 6, 52, 53 and immunoadsorption protocols have been successfully utilized in hypertensive patients with the a1-adrenergic receptor. 6 Autoantibody production is a hallmark characteristic of SLE disease, as %95% of SLE patients produce antibodies specific for nuclear components. 54 Autoantibodies similar to those found in SLE patients have also been found in patients with essential hypertension. [55] [56] [57] In the present study, MMF-treated SLE mice had lower anti-dsDNA autoantibody production coupled with attenuated hypertension. Long-term B-cell depletion with anti-CD20 also lowered anti-dsDNA IgG production and prevented the development of hypertension in SLE mice in a previous study by our laboratory. 17 Although these autoantibodies lead to immune complex formation and tissue inflammation, their precise role in the pathogenesis of hypertension remains to be elucidated. In the present study, SLE mice treated with MMF have less renal injury, as measured by albuminuria and histological assessment of glomerular damage. This is in agreement with previous studies in which MMF treatment delayed onset of renal injury and lowered proteinuria levels. 39 Clinically, patients with SLE who were administered MMF have been shown to have normal serum creatinine levels and decreased proteinuria. [58] [59] [60] The possibility exists that the prevention of renal injury is the result of the blood pressure-lowering effect of MMF; however, this is unlikely for several reasons. First, other established experimental models (ie, MRL/lpr) develop aggressive renal pathology that causes mortality typically by 20 weeks of age, but they do not develop hypertension. 61 Second, studies from our laboratory show that albuminuria does not track with hypertension; for example, early life ovariectomy of NZBWF1 mice ameliorates albuminuria while hypertension persists. 62 Importantly, this disconnect between nephritis and the development of hypertension during SLE has also been reported in humans. 63, 64 The present study further advances our understanding of the mechanisms by which renal and inflammatory changes, previously reported by us as promoting SLE-associated Consequently, a decrease in renal lymphocytes may lower the inflammation that is likely a driving factor in the development of hypertension. A potential mechanism that could lead to the reduction of lymphocytes in the kidneys is decreased immune complex deposition in the glomeruli. Treatment with MMF has been shown to decrease immune complex deposition in SLE mice. 40 In addition, MMF can inhibit the glycosylation and expression of adhesion molecules, which decreases the recruitment of lymphocytes into sites of inflammation. 20, 73 Data from both experimental and human hypertension indicate that renal immune cell infiltrates and renal injury contribute to the development of hypertension.
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Perspectives
The concept that adaptive immune system dysfunction associates with hypertension is now widely accepted. Both specific activating autoantibodies and circulating antibodies to nuclear antigens correlate with increased blood pressure in patients. In the present study, MMF treatment had an effect on circulating B lymphocytes, anti-dsDNA autoantibody production, renal injury, and hypertension. Based on the data from this study and previous studies by our laboratory, we believe that autoreactive B cells and pathogenic autoantibodies mechanistically contribute to the pathogenesis of hypertension during SLE. MMF is well established as an option for both induction and maintenance therapy in patients with SLE, and it may have the added benefit of helping to control blood pressure by depleting B cells and lowering autoantibody production. Hypertension affects a significant portion of SLE patients, and current clinical data suggest that patients with SLE have an extremely risk of high cardiovascular disease, making rigorous blood pressure control (ie, <130/80 mm Hg) of paramount importance in this patient population. 74 
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